Treatment Archives – Page 9 of 11 – Treatment Action Group

Activists Urge National TB Programs and Treatment Providers To Discontinue Use of Harmful Injectable Agents in TB Treatment

October 25, 2018
Chad Cipiti

Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.

Activists: Call On Your Countries To Use BDQ-Based Regimens to Treat TB

September 27, 2018
Chad Cipiti

GCTA, TAG, and DR-TB STAT developed this letter template to help activists to call for bedaquiline-based, injectable-free regimens in their countries. Please download this template letter here and use it in your country to advocate for the best care possible for people with drug-resistant TB.

TAGline Spring 2018

April 10, 2018
Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.

In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration

April 3, 2018
Chad Cipiti

By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…

It’s up to You, New York: Moving towards HCV Elimination in the Empire State

April 2, 2018
Chad Cipiti

By Annette Gaudino Governor Andrew Cuomo’s March 16 announcement committing New York State (NYS) to ending the hepatitis C virus (HCV) epidemic was the culmination of years of advocacy on a path that paralleled—and is built upon—the state’s nation leading…

World Health Organization Guidelines for the Treatment of Multidrug-Resistant Tuberculosis

February 1, 2018
Dorrit Walsh

Letter to Dr. Tedros Adhanom Ghebreyesus, Director-General, WHO, and Dr. Tereza Kasaeva, Global TB Program Director.

Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, and the Search for Solutions

November 30, 2017
Chad Cipiti

On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy. Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and…

HCV Genotypes

February 6, 2017
Chad Cipiti

February 2017 What are genotypes? A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat…

Viekira XR and Technivie Fact Sheet

February 2, 2017
Chad Cipiti

Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…

Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

January 24, 2017
Chad Cipiti

Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.